Department of Biochemistry and Genetics, La Trobe University, Bundoora, VIC 3086, Australia.
Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Int J Mol Sci. 2021 Apr 26;22(9):4501. doi: 10.3390/ijms22094501.
Cancer cachexia is a common condition in many cancer patients, particularly those with advanced disease. Cancer cachexia patients are generally less tolerant to chemotherapies and radiotherapies, largely limiting their treatment options. While the search for treatments of this condition are ongoing, standards for the efficacy of treatments have yet to be developed. Current diagnostic criteria for cancer cachexia are primarily based on loss of body mass and muscle function. However, these criteria are rather limiting, and in time, when weight loss is noticeable, it may be too late for treatment. Consequently, biomarkers for cancer cachexia would be valuable adjuncts to current diagnostic criteria, and for assessing potential treatments. Using high throughput methods such as "omics approaches", a plethora of potential biomarkers have been identified. This article reviews and summarizes current studies of biomarkers for cancer cachexia.
癌症恶病质是许多癌症患者的常见病症，尤其是晚期癌症患者。癌症恶病质患者通常对化疗和放疗的耐受性较低，这在很大程度上限制了他们的治疗选择。虽然目前正在寻找治疗这种疾病的方法，但尚未制定治疗效果的标准。目前癌症恶病质的诊断标准主要基于体重和肌肉功能的丧失。然而，这些标准相当有限，而且随着时间的推移，当体重减轻变得明显时，治疗可能已经为时过晚。因此，癌症恶病质的生物标志物将是对当前诊断标准的有价值的补充，并且可用于评估潜在的治疗方法。使用高通量方法（如“组学方法”），已经确定了大量潜在的生物标志物。本文综述和总结了目前癌症恶病质生物标志物的研究。
